A booster vaccination with the vaccine from Biontech and Pfizer provides significant protection against the omicron variant of the coronavirus in children between the ages of five and 11, according to a study. The blood analysis would show a 36-fold increase in omicron antibodies, the two companies announced on Maundy Thursday.
The pharmaceutical companies are therefore planning to apply for emergency authorization for a third dose of vaccine for the age group of five to 11 years in the coming days. Further applications to global regulatory authorities – including the European Medicines Agency (EMA) – will follow.
A study published in the New England Journal of Medicine at the beginning of April showed that two partial vaccinations with the mRNA vaccine from Pfizer/Biontech protect children and young people well – including against the omicron variant. BNT162b2 (that’s what the vaccine is called) cuts the risk of hospitalizations from omicron infections in children between the ages of five and 11 by two-thirds, the report said.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
